BMRA logo

BIOMERICA INC

BMRANASDAQ
πŸ† #4889 by market capUS Equity
$1.70β–² $0.02 (+1.19%)
Market closed Β· at close
πŸ””
Track BMRA
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 1.2%
7dβ–Ό 0.6%
14dβ–Ό 6.6%
30dβ–Ό 26.6%
ytdβ–Ό 32.0%
1yβ–Ό 43.1%
🏦Market Cap
$8M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-16.2%
Declining
πŸ“ŠGross Margin
8.1%
Thin
πŸ’΅FCF Margin
81.5%
Strong
βš–οΈP/S Ratio
1.8x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$1.70 – $1.70
52-Week Range
$1.45 – $3.09
Volume (shares)
218
Avg Volume (shares)
β€”
Shares Outstanding
4.6M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$4M
Last Q Revenue
$1M
P/E Ratio
β€”
P/S Ratio
1.8x
EPS (TTM)
$-1.26
Dividend Yield
β€”
Dilution (1yr)
+13.3%
BMRA logo

BIOMERICA INC

BMRA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$4Mβ–Ό βˆ’16.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
8.1%β–Ό βˆ’13.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$5Mβ–² +3.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$3Mβ–Ό βˆ’11.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.3Mβ–² +13.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$407Kβ–Ό βˆ’$2M YoY
StockOtter Β· stockotter.space

About BIOMERICA INC

Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.